Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Vedanta Biosciences to Present at Upcoming Investor Conferences


Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences:

William Blair Biotech Focus Conference
Dates: July 12-13, 2022
Location: St. Regis Hotel, New York, NY
A pre-recorded fireside chat will be made available on the William Blair conference website starting on Monday, July 11, 2022.

SVB Securities Biopharma Private Company Connect
Dates: July 20-21, 2022
Virtual 1x1 meetings only

About Vedanta Biosciences

Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company's clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, food allergy, liver disease, and cancer. These investigational therapies are grounded in pioneering research ? published in leading journals including Science, Nature, and Cell ? to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 45 patents and has built what it believes is one of the largest libraries of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies, and CGMP-compliant manufacturing of oral Live Biotherapeutic Product (LBP) candidates containing pure, clonally-derived bacterial consortia in powdered form. Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of the cross-talk between the microbiome and the immune system.


These press releases may also interest you

at 17:15
Dr. Neeraj Agarwal will act as a scientific advisor for Vial's Oncology CRO alongside Dr. Guru Sonpavde, Dr. Arati Rao, and Dr. Antoni Ribas. Together, they will lend their expertise to the Vial team as Vial continues to expand their Oncology CRO....

at 16:20
Earlier today the Senate voted to pass the Inflation Reduction Act of 2022, a bill that includes several key provisions to lower the prices of prescription drugs. AARP Pennsylvania thanks Senator Bob Casey for supporting this critical legislation and...

at 16:04
Today, the United States Senate passed the Inflation Reduction Act of 2022, and following the vote, U.S. Conference of Mayors CEO and Executive Director Tom Cochran issued this statement:...

at 15:46
Blue Cross Blue Shield Association President and CEO Kim Keck issued the following statement today in response to the passage of the Inflation Reduction Act, which extends Affordable Care Act (ACA) tax credits for three years....

at 04:10
Amgen  today announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World...

at 04:10
The protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol used in the National Lung Cancer Screening Trial,...



News published on 7 july 2022 at 07:05 and distributed by: